Merz Rejects US Interference in German Pharmaceutical Policy
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
The US Trade Representative's investigation into alleged underpayment of innovative medicines by Germany has jeopardized the 15% tariff ceiling agreement between the EU and the US; Prime Minister Merz emphasized that the decision is entirely an internal matter.
Mertz rejects US claims about drug prices in GermanyGerman Chancellor Friedrich Merz said that the decision to reimburse the cost of medicines is an internal matter of the country. The United States has started investigation into pharmaceutical prices in Germany.
Germany's Chancellor Friedrich Merz has criticized the initiation of an investigation by the United States Government into the prices of innovative pharmaceuticals in the German country, arguing possible discriminatory treatment of their trade, and has argued that the issue of medical insurance and drug reimbursements is an internal issue.
Germany's Chancellor Friedrich Merz has criticized the initiation of an investigation by the US government into the prices of innovative pharmaceuticals in the German country, arguing possible discriminatory treatment of their trade, and has argued that the issue of medical insurance and drug reimbursements is an internal issue.In this way, he has rejected the Trump administration's decision on the health management of medicines in Germany, alth…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
